Key result
The pharmacokinetics of glimepiride are altered in renal disease but may not be seriously affected in patients with liver disease.
Why the study?
Does glimepiride have altered pharmacokinetics in NIDDM patients with kidney or liver disease?
Population
NIDDM patients with kidney or liver disease
Design
Review
Authors
Loading...
May warrant renal dose adjustments; leaves open prospective PK confirmation in hepatic disease.
Does glimepiride have altered pharmacokinetics in NIDDM patients with kidney or liver disease?
Glimepiride pharmacokinetics are altered in patients with renal disease but appear unaffected in those with liver disease, which may inform dosing in these high-risk NIDDM patients.
Bernd Rosenkranz (1996) conducted a review in Non-insulin-dependent diabetes mellitus (NIDDM) with kidney or liver disease. Glimepiride vs. Healthy subjects / normal renal function was evaluated on Pharmacokinetics and fasting blood glucose. The pharmacokinetics of glimepiride are altered in renal disease but may not be seriously affected in patients with liver disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: